Marc Klein

Marc Klein

Auto-generated profile, based on publicly available information

Marc Klein

Service EDN, CHU de Nancy, 54500 Vandœuvre-Lès-Nancy, France

Research Focus & Metrics

Representative Publications

View All Publications
1 March 2008 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
MMM M Muresan
M M Muresan
POP Olivier
P Olivier
JLJ Leclere
J Leclere
FSF Sirveaux
F Sirveaux
LBLaurent Brunaud
Laurent Brunaud
GWG Weryha
G Weryha
The presence of distant metastases from differentiated thyroid carcinoma decreases the 10-year survival of patients by 50%. Bone metastases represent a frequent complication especially of follicular thyroid cancer and severely reduce the quality of life causing pain, fractures, and spinal cord compression. Diagnosis is established by correlating clinical suspicion with imaging. Imaging is essential to detect, localize, and assess the extension of the lesions and should be used in conjunction with clinical evidence. Bone metastases are typically associated with elevated markers of bone turnover, but these markers have not been evaluated in differentiated thyroid cancer. Skeletal and whole-body magnetic resonance imaging and fusion 2-deoxy-2-[18F]fluoro-d-glucose whole-body positron emission tomography/computed tomography (PET/CT) are the best anatomic and functional imaging techniques available in specialized centers. For well-differentiated lesions, iodine-PET scan combined 124I-PET/CT is the newest imaging development and 131I is the first line of treatment. Bisphosphonates reduce the complications rate and pain, alone or in combination with radioiodine, radionuclides, or external beam radiotherapy and should be employed. Surgery and novel minimally invasive consolidation techniques demand an appropriate patient selection for best results on a multimodal approach. Basic research on interactions between tumor cells and bone microenvironment are identifying potential novel targets for future more effective therapeutic interventions for less differentiated tumors.

1 December 2008 in Surgery
Verified
Journal Article
Closed access
LBLaurent Brunaud
Laurent Brunaud
AAAhmet Ayav
Ahmet Ayav
RZRasa Zarnegar
Rasa Zarnegar
ARAnthony Rouers
Anthony Rouers
MKMarc Klein
Marc Klein
LBLaurent Bresler
Laurent Bresler

29 December 2010 in Glia
Verified
Journal Article
Closed access
PDF file
DBDoreen Braun
Doreen Braun
AKAnita Kinne
Anita Kinne
ABAnja U. Bräuer
Anja U. Bräuer
RSRemy Sapin
Remy Sapin
MKMarc O. Klein
Marc O. Klein
USUlrich Schweizer
Ulrich Schweizer

1 March 2006 in Endocrinology
Verified
Journal Article
Closed access
Lutz SchomburgLutz Schomburg
Lutz Schomburg
CRCornelia Riese
Cornelia Riese
MMMarten Michaelis
Marten Michaelis
EGEmine Griebert
Emine Griebert
MKMarc O. Klein
Marc O. Klein
JKJosef Köhrle
Josef Köhrle
The thyroid gland is rich in selenium (Se) and expresses a variety of selenoproteins that are involved in antioxidative defense and metabolism of thyroid hormones (TH). Se deficiency impairs regular synthesis of selenoproteins and adequate TH metabolism. We recently generated mice that lack the plasma Se carrier, selenoprotein P (SePP). SePP-knockout mice display decreased serum Se levels and manifest growth defects and neurological abnormalities partly reminiscent of thyroid gland dysfunction or profound hypothyroidism. Thus, we probed the TH axis in developing and adult SePP-knockout mice. Surprisingly, expression of Se-dependent 5'-deiodinase type 1 was only slightly altered in liver, kidney, or thyroid at postnatal d 60, and 5'-deiodinase type 2 activity in brain was normal in SePP-knockout mice. Thyroid gland morphology, thyroid glutathione peroxidase activity, thyroid Se concentration, and serum levels of TSH, T4, or T3 were within normal range. Pituitary TSHbeta transcripts and hepatic 5'-deiodinase type 1 mRNA levels were unchanged, indicating regular T3 bioactivity in thyrotropes and hepatocytes. Cerebellar granule cell migration as a sensitive indicator of local T3 action during development was undisturbed. Collectively, these findings demonstrate that low levels of serum Se or SePP in the absence of other challenges do not necessarily interfere with regular functioning of the TH axis. 5'-deiodinase isozymes are preferentially supplied, and Se-dependent enzymes in the thyroid are even less-dependent on serum levels of Se or SePP than in brain. This indicates a top priority of the thyroid gland and its selenoenzymes with respect to the hierarchical Se supply within the organism.

28 September 2011 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
DBDoreen Braun
Doreen Braun
EWEva K. Wirth
Eva K. Wirth
FWFranziska Wohlgemuth
Franziska Wohlgemuth
NRNathalie Reix
Nathalie Reix
MKMarc O. Klein
Marc O. Klein
USUlrich Schweizer
Ulrich Schweizer
LAT2 (system L amino acid transporter 2) is composed of the subunits Slc7a8/Lat2 and Slc3a2/4F2hc. This transporter is highly expressed along the basolateral membranes of absorptive epithelia in kidney and small intestine, but is also abundant in the brain. Lat2 is an energy-independent exchanger of neutral amino acids, and was shown to transport thyroid hormones. We report in the present paper that targeted inactivation of Slc7a8 leads to increased urinary loss of small neutral amino acids. Development and growth of Slc7a8−/− mice appears normal, suggesting functional compensation of neutral amino acid transport by alternative transporters in kidney, intestine and placenta. Movement co-ordination is slightly impaired in mutant mice, although cerebellar development and structure remained inconspicuous. Circulating thyroid hormones, thyrotropin and thyroid hormone-responsive genes remained unchanged in Slc7a8−/− mice, possibly because of functional compensation by the thyroid hormone transporter Mct8 (monocarboxylate transporter 8), which is co-expressed in many cell types. The reason for the mild neurological phenotype remains unresolved.

1 December 2007 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
ETErwan Thouënnon
Erwan Thouënnon
AEAbdel G. Elkahloun
Abdel G. Elkahloun
JGJohann Guillemot
Johann Guillemot
ARAnne-Paule ROQUEPLO
Anne-Paule ROQUEPLO
JBJérôme Bertherat
Jérôme Bertherat
YAYoussef Anouar
Youssef Anouar
Context: Pheochromocytomas are catecholamine-producing tumors that are generally benign but that can also present as or develop into malignancy. Occurrence of malignant pheochromocytomas can only be asserted by imaging of metastatic lesions. Objectives: We conducted a gene expression profiling of benign and malignant tumors to identify a gene signature that would allow us to discriminate benign from malignant pheochromocytomas and to gain a better understanding of tumorigenic pathways associated with malignancy. Design: A total of 36 patients with pheochromocytoma was studied retrospectively. There were 18 (nine benign and nine malignant) tumors used for gene expression profiling on pangenomic oligonucleotide microarrays. Results: We identified and validated a set of predictor genes that could accurately distinguish the two tumor subtypes through unsupervised clustering. Most of the differentially expressed genes were down-regulated in malignant tumors, and several of these genes encoded neuroendocrine factors involved in prominent characteristics of chromaffin cell biology. In particular, the expression of two key processing enzymes of trophic peptides, peptidylglycine α-amidating monooxygenase and glutaminyl-peptide cyclotransferase, was reduced in malignant pheochromocytomas. Conclusion: The gene expression profiling of benign and malignant pheochromocytomas clearly identified a set of genes that could be used as a prognostic multi-marker and revealed that the expression of several genes encoding neuroendocrine proteins was reduced in malignant compared with benign tumors.